Skip to main content
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Molecular Targets Collections
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Journals
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Molecular Targets Collections
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Research Article

Nanoformulation of Olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation

Anne L van de Ven, Shifalika Tangutoori, Paige Baldwin, Ju Qiao, Codi Gharagouzloo, Nina Seitzer, John G. Clohessy, G. Mike Makrigiorgos, Robert Cormack, Pier Paolo Pandolfi and Srinivas Sridhar
Anne L van de Ven
Department of Physics, Northeastern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shifalika Tangutoori
Nanomedicine Science & Technology Center, Northeastern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paige Baldwin
Nanomedicine Science & Technology Center, Northeastern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ju Qiao
Department of Mechanical and Industrial Engineering, Northeastern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Codi Gharagouzloo
Department of Bioengineering, Northeastern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Seitzer
Cancer Research Institute, Beth Israel Deaconess Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John G. Clohessy
Cancer Research Institute, Beth Israel Deaconess Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Mike Makrigiorgos
Department of Radiation Oncology, Dana-Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Cormack
Department of Radiation Oncology, Dana Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pier Paolo Pandolfi
Cancer Research Institute, Beth Israel Deaconess Medical Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srinivas Sridhar
Department of Physics, Northeastern University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: s.sridhar@northeastern.edu
DOI: 10.1158/1535-7163.MCT-16-0740
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The use of PARP inhibitors in combination with radiation therapy is a promising strategy to locally enhance DNA-damage in tumors. Here we show that radiation-resistant cells and tumors derived from a Pten/Trp53-deficient mouse model of advanced prostate cancer are rendered radiation-sensitive following treatment with NanoOlaparib, a lipid-based injectable nanoformulation of Olaparib. This enhancement in radiosensitivity is accompanied by radiation dose-dependent changes in γ-H2AX expression and is specific to NanoOlaparib alone. In animals, twice-weekly intravenous administration of NanoOlaparib results in significant tumor growth inhibition, whereas previous studies of oral Olaparib as monotherapy have shown no therapeutic efficacy. When NanoOlaparib is administered prior to radiation, a single dose of radiation is sufficient to triple the median mouse survival time compared to radiation only controls. Half of mice treated with NanoOlaparib + radiation achieved a complete response over the 13 week study duration. Using ferumoxytol as a surrogate nanoparticle, MRI studies revealed that NanoOlaparib enhances the intratumoral accumulation of systemically administered nanoparticles. NanoOlaparib-treated tumors showed up to 19-fold higher nanoparticle accumulation compared to untreated and radiation-only controls, suggesting that the in vivo efficacy of NanoOlaparib may be potentiated by its ability to enhance its own accumulation. Together, this data suggests that NanoOlaparib may be a promising new strategy for enhancing the radiosensitivity of radiation-resistant tumors lacking BRCA mutations, such as those with PTEN and TP53 deletions.

  • Received November 3, 2016.
  • Revision received March 9, 2017.
  • Accepted April 28, 2017.
  • Copyright ©2017, American Association for Cancer Research.
Next
Back to top

Published OnlineFirst May 12, 2017
doi: 10.1158/1535-7163.MCT-16-0740

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Nanoformulation of Olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
Citation Tools
Nanoformulation of Olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation
Anne L van de Ven, Shifalika Tangutoori, Paige Baldwin, Ju Qiao, Codi Gharagouzloo, Nina Seitzer, John G. Clohessy, G. Mike Makrigiorgos, Robert Cormack, Pier Paolo Pandolfi and Srinivas Sridhar
Mol Cancer Ther May 12 2017 DOI: 10.1158/1535-7163.MCT-16-0740

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Nanoformulation of Olaparib amplifies PARP inhibition and sensitizes PTEN/TP53-deficient prostate cancer to radiation
Anne L van de Ven, Shifalika Tangutoori, Paige Baldwin, Ju Qiao, Codi Gharagouzloo, Nina Seitzer, John G. Clohessy, G. Mike Makrigiorgos, Robert Cormack, Pier Paolo Pandolfi and Srinivas Sridhar
Mol Cancer Ther May 12 2017 DOI: 10.1158/1535-7163.MCT-16-0740
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Induction of telomere damage to treat pediatric brain tumors
  • Hypersensitivity of BRCA1/2-deficient cells to APTO-253
  • A synthetic BRCA2 peptide inhibits RAD51
Show more Research Article
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright 2016 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement